Fig. 4.

DCZ0415 treatment reduces prostate tumor growth and expression of PCNA and modulates EMT markers in NSG mouse models. Mice were subcutaneously injected with DU145 (5×10⁶) or PC3 (2 × 10⁶) cells to initiate tumor growth. When the volume of tumor reached ∼100mm³, the mice were treated with vehicle (control) or with DCZ0415 (50 mg/kg b. wt. on alternate days). (A). Photographs of DU145 and PC3 xenografts after treatment with vehicle or DCZ0415 at the termination of the experiment. (B). Weights of DU145 and PC3 xenografts at the termination of experiments for vehicle- and DCZ0415‐treated mice. Error bar indicates mean± SD, *p<0.001. (C). Growth kinetics of DU145 and PC3 xenografts in mice treated with vehicle or DCZ0415. Error bar indicates mean ± SD,*p < 0.001. (D&E). H&E and IHC staining for PCNA, vimentin, and E-cadherin in DU145 and PC3 xenografts of the vehicle or DCZ0145-treated mice. Scale bar: 20µm.